Search

Purpose: To report the efficacy and safety of interferon (IFN) α-2a in patients with cystoid macular edema (CME) associated with presumed ocular tuberculosis (TB).Methods: We reviewed the clinical records of 5 patients with presumed ocular TB who had been treated with IFN α-2a for recurrent CME during or after completion of anti-tubercular therapy. IFN α-2a was administered at an initial dose of 3 million IU per day and then tapered after the initial response. Treatment efficacy was assessed by central macular thickness (CMT) measurement using spectral-domain optical coherence tomography and visual acuity.Results: Three patients were men, and 2 were women. Patients were aged between 38 and 66 years. Mean CMT was 483 ± 178.6 μm at baseline, 302.3 ± 56 μm at 1 week, 312.3 ± 49.5 μm at 1 month, and 286.2 ± 31.9 μm at 3 months. Mean LogMAR visual acuity was 0.6 ± 0.4 at baseline, 0.4 ± 0.3 μm at 1 week, 0.3 ± 0.3 at 1 month, and 0.3 ± 0.3 at 3 months. The treatment was interrupted for 10 days because of neutropenia after 2 weeks in 1 patient and discontinued in another after 10 days because of intolerance. Total treatment duration was 3-24 months in the remaining 4 patients.Conclusion: The present small case series suggests that IFN α-2a may be an effective and safe therapeutic option for CME that is associated with presumed ocular TB. [ABSTRACT FROM AUTHOR]

Purpose: To describe the clinical and visual outcomes of juvenile idiopathic arthritis (JIA)-associated uveitis in adults and to examine risk factors for ongoing inflammation in adulthood. Methods: Medical records were reviewed for patients with JIA-associated uveitis who were >16 years old at the final visit (the last visit prior to data collection). Results: In total, 135 eyes of 77 patients (70 female, 7 male) were included. The mean age of patients at the final visit was 29.72 ± 11.27 years. The number of eyes with visual acuity of ≤20/50 and ≤20/200 at the final visit was 37 (28 %) and 20 (15 %), respectively; at least one ocular complication was present in 72 % of eyes. Band keratopathy was the most frequent complication (42 %), followed by cataract (25 %), posterior synechiae (22 %), maculopathy (22 %), ocular hypertension (13 %), and hypotony (5 %). At the final visit, patients who were >16 years of age at presentation to the Massachusetts Eye Research and Surgery Institution had more ocular complications and a greater degree of vision loss than patients who were ≤16 years of age. Ongoing inflammation at the final visit was noted in 40 patients (52 %). The presence of posterior synechiae, hypotony, cataract at presentation, and a history of cataract surgery prior to presentation were predictive of ongoing inflammation in adulthood in univariate analysis. The presence of hypotony and posterior synechiae at the initial visit were predictive factors in multivariate analysis. Conclusions: JIA-associated uveitis may be associated with ongoing inflammation, ocular complications, and severe visual impairment in adulthood. The presence of posterior synechiae and hypotony at the initial visit is predictive of ongoing inflammation. [ABSTRACT FROM AUTHOR]

Purpose To report the outcomes of tocilizumab treatment for refractory ocular inflammatory diseases. Methods A retrospective case series of 17 patients (28 eyes) diagnosed with recalcitrant ocular inflammatory diseases including uveitis (10 cases), scleritis (six cases) and orbital pseudotumour (one case), who received tocilizumab between April 2010 and March 2015. All patients were initiated with treatment of 4 mg/kg or 8 mg/kg tocilizumab. The primary outcome was absence of inflammation and achievement of steroid sparing at 6 and 9 months. Secondary outcomes were change in visual acuity and major adverse effects of tocilizumab causing discontinuation of the treatment. Results Mean age at initiation of tocilizumab was 41 ± 16 years. Prior to tocilizumab treatment, all patients underwent unsuccessful conventional immunosuppressive therapy while 94% of patients (16/17) failed treatment with various biological agents. After tocilizumab administration, control of inflammation and steroid sparing were achieved in 63% and 71% of uveitis patients at 6 and 9 months, while 50% of scleritis patients achieved the primary outcome at 6 and 9 months. Mean duration of tocilizumab therapy was 12.6 ± 10.0 (range, 2-35) months. Three of four patients who had a follow-up of at least 18 (range, 18-35) months experienced quiescent inflammation for up to 32 months of tocilizumab use until last visit. Four patients (24%) discontinued tocilizumab due to serious side effects including neutropenia, unacceptable dizziness and nausea, severe angioedema and severe abdominal pain. Conclusion Our series demonstrated moderate efficacy of tocilizumab in recalcitrant uveitis and scleritis. Serious adverse effects were not uncommon. [ABSTRACT FROM AUTHOR]

Objective: To evaluate the effect of phacoemulsification with intraocular lens (IOL) implantation on intraocular inflammation using laser flare photometer in eyes with uveitis. Materials and Methods: Sixty-six eyes of 55 consecutive patients followed-up at Istanbul University, Istanbul School of Medicine, Department of Ophthalmology, Uveitis Service undergoing phacoemulsification with posterior chamber intraocular lens implantation between December 2009 and April 2013 were included in this retrospective study. Clinical records of patients were analyzed for demographic data, pre-operative and post-operative best-corrected visual acuity (BCVA), intraocular pressure, and quantitative measurement of inflammation with laser flare photometry. Baseline evaluations were performed 1 day before surgery and follow-up examinations took place at 1, 7, 30, and 90 days after surgery. Main outcome measures were BCVA and quantitative measurement of intraocular inflammation with laser flare photometry. Results: Best-corrected visual acuity improved in 60 eyes and visual loss did not occur in any eye. Median intraocular flare value the day before surgery was 8.2 (range: 3.1-82.2) photons/ms. Postoperatively, median flare value initially increased to 16.8 (range: 0-158) photons/ms on day 1 which was a statistically significant increase compared to preoperative values. Thereafter decreased to 10.40 (range: 0-110) photons/ms on day 7, 11.25 (range: 4.4-145) photons/ms on day 30, and 8.1 (range: 0-84.6) photons/ms on day 90. There was no statistically significant difference between preoperative values and day 90. Conclusion: In uveitic eyes with well-controlled ocular inflammation before surgery, phacoemulsification with IOL implantation appears safe and effective as assessed by changes in the BCVA and laser flare photometry, an objective method to measure intraocular inflammation. [ABSTRACT FROM AUTHOR]